medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-106Research ArticleСтатьиКлиническая эффективность рабепразолаClinical efficacy of rabeprazoleПлотниковаЕ. Ю.PlotnikovaE. Yu.noemail@neicon.ruСухихА. С.SukhikhA. S.noemail@neicon.ruГрачеваТ. Ю.GrachyovaT. Yu.noemail@neicon.ruВологжанинаЛ. Г.VologzhaninaL. G.noemail@neicon.ruФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава РоссииРоссияKemerovo State Medical UniversityRussian FederationФГБОУ ВО «Пермский государственный медицинский университет» имени академика Е. А. Вагнера» Минздрава РоссииРоссияPerm State Medical University n.a. E. A. WagnerRussian Federation20172303201719Практическая гастроэнтерология4045Copyright © Плотникова Е.Ю., Сухих А.С., Грачева Т.Ю., Вологжанина Л.Г., 20172017Плотникова Е.Ю., Сухих А.С., Грачева Т.Ю., Вологжанина Л.Г.Plotnikova E.Y., Sukhikh A.S., Grachyova T.Y., Vologzhanina L.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/106

Ингибиторы протонной помпы широко применяются в клинической практике. Рабепразол является мощным и необратимым ингибитором Н+/К+-АТФазы (то есть протонного насоса) и показан для лечения кислотозависимых заболеваний. По результатам оценки фармакокинетики и фармакодинамики рабепразол обеспечивает выраженное подавление кислотности, начиная с первого приема, и его эффект сохраняется при многократном применении. Вследствие преимущественно неферментативного метаболизма рабепразол обладает низким потенциалом межлекарственных взаимодействий. Рабиет®-отечественный рабепразол, который является препаратом выбора как эффективный, качественный, безопасный и доступный по цене.

Proton pump inhibitors are widely used in clinical practice. Rabeprazole is a potent and irreversible inhibitor of H+/K+-AT-Pase (i.e. proton pump), and is indicated for the treatment of acid-dependent diseases. Based on the evaluation of pharmacokinetics and pharmacodynamics, rabeprazole provides a marked suppression of acidity, starting with the first dose, and its effect persists after repeated use. Due to predominantly non-enzymatic metabolism, rabeprazole has a low potential for inter-drug interactions. Rabiet® is a domestic rabeprazole, which is the drug of choice as effective, quality, safe and affordable.

ингибиторы протонной помпырабепразолкислотозависимые заболеванияРабиет®proton pump inhibitorsrabeprazoleacid-dependent diseasesRabiet®ReferencesSachs G, Chang HH, Rabon E et al. A non-electrogenic H+ pump in plasma membrane of hog stomach. J. Biol. Chem. 1976; 251: 7690-7698.Sachs G, Chang HH, Rabon E et al. A non-electrogenic H+ pump in plasma membrane of hog stomach. J. Biol. Chem. 1976; 251: 7690-7698.Parsons ME. Proton Pump Inhibitors. Gut. 2000; 47: 316.Parsons ME. Proton Pump Inhibitors. Gut. 2000; 47: 316.Fellenius E, Berglindh T, Sachs G et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking H+, K+ATPase. Nature. 1981; 290: 156-161.Fellenius E, Berglindh T, Sachs G et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking H+, K+ATPase. Nature. 1981; 290: 156-161.Olbe L, Haglund U, Leth R et al. Effect of substituted benzimidazole (H149/94) on gastric acid secretion in humans. Gastroenterology. 1982; 83: 193-198.Olbe L, Haglund U, Leth R et al. Effect of substituted benzimidazole (H149/94) on gastric acid secretion in humans. Gastroenterology. 1982; 83: 193-198.Robinson M. New-generation proton pump inhibitors: over-coming the limitations of early-generation agents. Eur. J. Gastroenterol. Hepatol. 2001; 13 (1) 6: S43-S47.Robinson M. New-generation proton pump inhibitors: over-coming the limitations of early-generation agents. Eur. J. Gastroenterol. Hepatol. 2001; 13 (1) 6: S43-S47.Luo JY, Niu CY, Wang XQ et al. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J. Gastroenterol. 2003; 9Luo JY, Niu CY, Wang XQ et al. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J. Gastroenterol. 2003; 9Лопина О. Д., Сереброва С. Ю. Основные фармакокинетические характеристики ингибиторов протонного насоса и эффективность их действия. Пособие для врачей. 2016, М: ООО «Принталлогги», 40 с.Лопина О. Д., Сереброва С. Ю. Основные фармакокинетические характеристики ингибиторов протонного насоса и эффективность их действия. Пособие для врачей. 2016, М: ООО «Принталлогги», 40 с.Fass R. Medical Management of GERD. DDW. 2002; 122: 625-632.Fass R. Medical Management of GERD. DDW. 2002; 122: 625-632.Cash B. Clinical Applications of Proton-Pump Inhibitors. American College of Gastroenterology 67th Annual Scientific Meeting.- URL: http://www.medscape. org/viewarticle/463422.Cash B. Clinical Applications of Proton-Pump Inhibitors. American College of Gastroenterology 67th Annual Scientific Meeting.- URL: http://www.medscape. org/viewarticle/463422.Paterson W. L. Improving the Management of GERD. Evidence-based therapeutic strategies, American Gastroenterological Association, Consensus Development Panel, Consensus Opinion in Gastroenterology, 2002.- URL: http://www.gastro.org/edu/ GERDmonograph.pdf.Paterson W. L. Improving the Management of GERD. Evidence-based therapeutic strategies, American Gastroenterological Association, Consensus Development Panel, Consensus Opinion in Gastroenterology, 2002.- URL: http://www.gastro.org/edu/ GERDmonograph.pdf.Castell DO, Fennerty MB, Johnson DA, Kahrilas PJ. A critical analysis of the new PPI esomeprazole. AGA New Drug Review. 2001; September: 3-20.Castell DO, Fennerty MB, Johnson DA, Kahrilas PJ. A critical analysis of the new PPI esomeprazole. AGA New Drug Review. 2001; September: 3-20.Adachi K, Hashimoto T, Hamamoto N et al. Symptom relied in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J. Gastroenterol. Hepatol. 2003; 18 (12): 1392-1398.Adachi K, Hashimoto T, Hamamoto N et al. Symptom relied in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J. Gastroenterol. Hepatol. 2003; 18 (12): 1392-1398.Holtmann G, Bytzer P, Metz M et al. A randomized, double-blind, comparative study of standart-dose rabeprazole and high-dose omeprasole in gastro-esophageal reflux disease. Aliment. Pharmacol. Ther. 2002; 16: 479-485.Holtmann G, Bytzer P, Metz M et al. A randomized, double-blind, comparative study of standart-dose rabeprazole and high-dose omeprasole in gastro-esophageal reflux disease. Aliment. Pharmacol. Ther. 2002; 16: 479-485.Yamano H, Yanagihara S, Matsushita H. Clinical relevance of antisecretory effect of a novel PPI, rabeprazole, in GERD patients with respect to 2C 19 genotypes. Gut. 2004; 53 (1): A106.Yamano H, Yanagihara S, Matsushita H. Clinical relevance of antisecretory effect of a novel PPI, rabeprazole, in GERD patients with respect to 2C 19 genotypes. Gut. 2004; 53 (1): A106.Gardner JD, Perdomo C, Sloan S et al. Integrated acidity and rabeprazole pharmacology. Aliment. Pharmacol. Ther. 2002; 16: 455-464.Gardner JD, Perdomo C, Sloan S et al. Integrated acidity and rabeprazole pharmacology. Aliment. Pharmacol. Ther. 2002; 16: 455-464.Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am. J. Gastroenterol. 1998; 93: 763-767.Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am. J. Gastroenterol. 1998; 93: 763-767.Williams MP, Sercombe J, Hamilton MI, Pouder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 1998; 12: 1079-1089.Williams MP, Sercombe J, Hamilton MI, Pouder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 1998; 12: 1079-1089.Yanagihara S, Matsushita H, Yamano H. CYP 2C 19 genotype and pharmacokinetics of a novel proton pump inhibitor, rabeprazole, with respect to acid suppression in GERD patients. Gut. 2004; 53 (VI): A107.Yanagihara S, Matsushita H, Yamano H. CYP 2C 19 genotype and pharmacokinetics of a novel proton pump inhibitor, rabeprazole, with respect to acid suppression in GERD patients. Gut. 2004; 53 (VI): A107.Kawakami Y, Akahane T, Yamaguchi M et al. In vitro activities of of rabeprazole, a novel proton pump inhibitor, and its thio-ether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 2 (44): 458-461.Kawakami Y, Akahane T, Yamaguchi M et al. In vitro activities of of rabeprazole, a novel proton pump inhibitor, and its thio-ether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 2 (44): 458-461.Bensancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric of the gastric H, K-ATP-ase with extra cytoplasmic thiol reagents. J. Biol. Chem. 1997; 272: 22438-22446.Bensancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric of the gastric H, K-ATP-ase with extra cytoplasmic thiol reagents. J. Biol. Chem. 1997; 272: 22438-22446.Ivashkin V, TrukhmanovA, Maev I. On-demand long term management of patients suffering from non-erosive GERD with rabeprazole mg. Gut. 2004; 36 (l): A101.Ivashkin V, TrukhmanovA, Maev I. On-demand long term management of patients suffering from non-erosive GERD with rabeprazole mg. Gut. 2004; 36 (l): A101.Cloud ML, Enas N, Humphries TJ, Bassion S. The Ra-beprazole Study Group. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophage-al reflux disease (GERD). Dig. Dis. Sci. 1998; 43: 993-1000.Cloud ML, Enas N, Humphries TJ, Bassion S. The Ra-beprazole Study Group. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophage-al reflux disease (GERD). Dig. Dis. Sci. 1998; 43: 993-1000.Inamori M, Togawa J-I, Takahashi H et al. Comparisom on intragastric pH of a single dose of omeprasole or rabeprazole: Which is suitable for on-demand therapy? J. Gastroenterol. Hepatol. 2003; 18: 1034.Inamori M, Togawa J-I, Takahashi H et al. Comparisom on intragastric pH of a single dose of omeprasole or rabeprazole: Which is suitable for on-demand therapy? J. Gastroenterol. Hepatol. 2003; 18: 1034.Maiti R, Jaida J, Israel PLJ, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. The Journal of Pharmacology & Pharmacotherapeutics. 2011; 2 (3): 150-157.Maiti R, Jaida J, Israel PLJ, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. The Journal of Pharmacology & Pharmacotherapeutics. 2011; 2 (3): 150-157.Robinson M, Cheung E, Murthy A, Jokubaitis L. Rabeprazole efficacy in erosive GERD: subgroup analyses from the future of acid suppression therapy (F.A.S.T.) trial. Am.J. Gastroenterol. 2001; 96 (1): S33-S34.Robinson M, Cheung E, Murthy A, Jokubaitis L. Rabeprazole efficacy in erosive GERD: subgroup analyses from the future of acid suppression therapy (F.A.S.T.) trial. Am.J. Gastroenterol. 2001; 96 (1): S33-S34.Thjodleifsson B, Morocutti A, Bardhan KD. A 5-year, double-blind, randomized comparison of rabeprazole and omeprazole in GORD maintenance treatment efficacy results. Gut. 2002; 50: a4-a7.Thjodleifsson B, Morocutti A, Bardhan KD. A 5-year, double-blind, randomized comparison of rabeprazole and omeprazole in GORD maintenance treatment efficacy results. Gut. 2002; 50: a4-a7.Старостин Б.Д. Step in-терапия при ГЭРБ. Гастроэнтерология Санкт-Петербурга. 2003; 2-3: 158 (591).Старостин Б.Д. Step in-терапия при ГЭРБ. Гастроэнтерология Санкт-Петербурга. 2003; 2-3: 158 (591).Dekkers CPM, Beker JA, Thjodleifsson B et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer, a European multicentre study. Aliment. Pharmacol. Ther. 1999; 13: 179-186.Dekkers CPM, Beker JA, Thjodleifsson B et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer, a European multicentre study. Aliment. Pharmacol. Ther. 1999; 13: 179-186.Katz PO, Frissora C. The pharmacology and clinical relevance of proton pump inhibitors. Curr. Gastroenterol. Rep. 2002; 4: 459-462.Katz PO, Frissora C. The pharmacology and clinical relevance of proton pump inhibitors. Curr. Gastroenterol. Rep. 2002; 4: 459-462.Stack WA, Knifton A, Thirlwell D et al. Safety and efficacy of rabeprazole in combination with four antibiotics for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am.J. Gastroenterol. 1998; 93: 1909-1913.Stack WA, Knifton A, Thirlwell D et al. Safety and efficacy of rabeprazole in combination with four antibiotics for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am.J. Gastroenterol. 1998; 93: 1909-1913.Kawakami Y, Akahane T, Yamaguchi M et al. In vitro activities of of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recen t clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 44 (2): 458-461.Kawakami Y, Akahane T, Yamaguchi M et al. In vitro activities of of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recen t clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 44 (2): 458-461.Бабак О. Я. Сравнительная характеристика клинической эффективности рабепразола и других ингибиторов протонной помпы по результатам мета-анализа. Сучасна гастроентерология. 2007; 3 (35): 32-37.Бабак О. Я. Сравнительная характеристика клинической эффективности рабепразола и других ингибиторов протонной помпы по результатам мета-анализа. Сучасна гастроентерология. 2007; 3 (35): 32-37.Ng F, Lam K, Wong S et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion. 2008; 77: 173-7.Ng F, Lam K, Wong S et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion. 2008; 77: 173-7.Ray W, Murray K, Griffin M et al. Outcomes with concurrent use ofclopidogrel and proton-pump inhibitors: a cohort study. Ann. Intern. Med. 2010; 152: 337-45.Ray W, Murray K, Griffin M et al. Outcomes with concurrent use ofclopidogrel and proton-pump inhibitors: a cohort study. Ann. Intern. Med. 2010; 152: 337-45.Lanas A, Garcia-Rodriguez L, Arroyo M et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007; 102: 507-15.Lanas A, Garcia-Rodriguez L, Arroyo M et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 2007; 102: 507-15.Blume H, Donath F, Warnke A, Schug B. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Safety, Volume 29. 2006; 9 (16): 769-784.Blume H, Donath F, Warnke A, Schug B. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Safety, Volume 29. 2006; 9 (16): 769-784.Hokimoto S, Ogawa H, Yamamoto K et al. Is Impact of Proton Pump Inhibitor on Platelet Reactivity to Clopidogrel A Class Effect? Abstract 5010. Circulation. 2009; 120: S 1033.Hokimoto S, Ogawa H, Yamamoto K et al. Is Impact of Proton Pump Inhibitor on Platelet Reactivity to Clopidogrel A Class Effect? Abstract 5010. Circulation. 2009; 120: S 1033.Kenngott S, Olze R, Kollmer M et al. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur. J. Med. Res. 2010 May 18; 15 (5): 220-4.Kenngott S, Olze R, Kollmer M et al. Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur. J. Med. Res. 2010 May 18; 15 (5): 220-4.Hsiao F, Mullins C, Wen Y et al. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf. 2011 Oct; 20 (10): 1043-9.Hsiao F, Mullins C, Wen Y et al. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf. 2011 Oct; 20 (10): 1043-9.Shen L, Wu F et al. Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and Proton Pump Inhibitors in Patients of Acute Coronary Syndrome in Taiwan. Br. J. Clin. Pharmacol. 2012 Feb 24; 74 (5): 824-834.Shen L, Wu F et al. Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and Proton Pump Inhibitors in Patients of Acute Coronary Syndrome in Taiwan. Br. J. Clin. Pharmacol. 2012 Feb 24; 74 (5): 824-834.Fujishiro M, Higuchi K, Kato M, Kinoshita Y, Iwakiri R, Watanabe T, Takeuchi T, Sugisaki N, Okada Y, Ogawa H, Arakawa T, Fujimoto K. Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial. J. Clin. Biochem. Nutr. 2015 May; 56 (3): 228-239.Fujishiro M, Higuchi K, Kato M, Kinoshita Y, Iwakiri R, Watanabe T, Takeuchi T, Sugisaki N, Okada Y, Ogawa H, Arakawa T, Fujimoto K. Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial. J. Clin. Biochem. Nutr. 2015 May; 56 (3): 228-239.Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev. Gastroenterology & Hepatology. 2012; 6 (4): 423-435.Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev. Gastroenterology & Hepatology. 2012; 6 (4): 423-435.

The authors declare that there are no conflicts of interest present.